

Highlights of This Issue 5145

SPECIAL FEATURES

CCR Translations

- 5147** Blocking Immunosuppressive Checkpoints for Glioma Therapy: The More the Merrier!
Maria G. Castro, Gregory J. Baker, and Pedro R. Lowenstein
See related article, p. 5290

CCR New Strategies



- 5150** New Strategies in Ovarian Cancer: Translating the Molecular Complexity of Ovarian Cancer into Treatment Advances
Joyce Liu and Ursula A. Matulonis

Molecular Pathways

- 5157** Molecular Pathways: Myeloid Complicity in Cancer
Ingunn M. Stromnes, Philip D. Greenberg, and Sunil R. Hingorani

CCR Focus

- 5172** The Lymphoma Medicine Cabinet
Susan E. Bates
- 5173** Putting the Clinical and Biological Heterogeneity of Non-Hodgkin Lymphoma into Context
Owen A. O'Connor and Kensei Tobinai
- 5182** Precision Treatment of Distinct Molecular Subtypes of Diffuse Large B-cell Lymphoma: Ascribing Treatment Based on the Molecular Phenotype
Kieron Dunleavy, Mark Roschewski, and Wyndham H. Wilson
- 5194** New Paradigms in Mantle Cell Lymphoma: Is It Time to Risk-Stratify Treatment Based on the Proliferative Signature?
Martin Dreyling, Simone Ferrero, Niklas Vogt, and Wolfram Klapper on behalf of the European Mantle Cell Lymphoma Network

- 5207** Emerging Role of Infectious Etiologies in the Pathogenesis of Marginal Zone B-cell Lymphomas

Emanuele Zucca, Francesco Bertoni, Barbara Vannata, and Franco Cavalli

- 5217** Human T-cell Lymphotropic Virus Type I–Associated Adult T-cell Leukemia–Lymphoma: New Directions in Clinical Research

Kunihiro Tsukasaki and Kensei Tobinai

- 5226** Are We Nearing an Era of Chemotherapy-Free Management of Indolent Lymphoma?

Emmanuel Bachy and Gilles Salles

- 5240** Changing the Paradigms of Treatment in Peripheral T-cell Lymphoma: From Biology to Clinical Practice

Owen A. O'Connor, Govind Bhagat, Karthik Ganapathi, Martin Bjerregaard Pedersen, Francesco D'Amore, Dejan Radeski, and Susan E. Bates

CANCER THERAPY: CLINICAL

- 5255** A Phase I Study of the First-in-Class Antimitochondrial Metabolism Agent, CPI-613, in Patients with Advanced Hematologic Malignancies
Timothy S. Pardee, King Lee, John Luddy, Claudia Maturo, Robert Rodriguez, Scott Isom, Lance D. Miller, Kristin M. Stadelman, Denise Levitan, David Hurd, Leslie R. Ellis, Robin Harrelson, Megan Manuel, Sarah Dralle, Susan Lyerly, and Bayard L. Powell

PERSONALIZED MEDICINE AND IMAGING

- 5265** Gene Signature–Guided Dasatinib Therapy in Metastatic Breast Cancer
Lajos Pusztai, Stacy Moulder, Mehmet Altan, Danielle Kwiatkowski, Vicente Valero, Naoto T. Ueno, Francisco J. Esteva, Rony Avritscher, Yuan Qi, Lewis Strauss, Gabriel N. Hortobagyi, Christos Hatzis, and W. Fraser Symmans

Table of Contents

- 5272** Development and Validation of a Gene Profile Predicting Benefit of Postmastectomy Radiotherapy in Patients with High-Risk Breast Cancer: A Study of Gene Expression in the DBCG82bc Cohort
Trine Tramm, Hayat Mohammed, Simen Myhre, Marianne Kyndi, Jan Alsner, Anne-Lise Børresen-Dale, Therese Sørli, Arnaldo Frigessi, and Jens Overgaard

- 5281** Pharmacogenomic Modeling of Circulating Tumor and Invasive Cells for Prediction of Chemotherapy Response and Resistance in Pancreatic Cancer



Kenneth H. Yu, Mark Ricigliano, Manuel Hidalgo, Ghassan K. Abou-Alfa, Maeve A. Lowery, Leonard B. Saltz, Joseph F. Crotty, Kristen Gary, Brandon Cooper, Rena Lapidus, Mariola Sadowska, and Eileen M. O'Reilly

CANCER THERAPY: PRECLINICAL

- 5290** Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
Derek A. Wainwright, Alan L. Chang, Mahua Dey, Irina V. Balyasnikova, Chung Kwon Kim, Alex Tobias, Yu Cheng, Julius W. Kim, Jian Qiao, Lingjiao Zhang, Yu Han, and Maciej S. Lesniak
See related commentary, p. 5147

BIOLOGY OF HUMAN TUMORS

- 5302** Overdetection of Recurrence after Radical Prostatectomy: Estimates Based on Patient and Tumor Characteristics
Jing Xia, Bruce J. Trock, Roman Gulati, Leslie Mallinger, Matthew R. Cooperberg, Peter R. Carroll, H. Ballentine Carter, and Ruth Etzioni

- 5311** Identification of Differentially Expressed Long Noncoding RNAs in Bladder Cancer
Stefan Peter, Edyta Borkowska, Ross M. Drayton, Callum P. Rakhit, Aidan Noon, Wei Chen, and James WF Catto

- 5322** Mismatch Repair Status and *BRAF* Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
Sabine Venderbosch, Iris D. Nagtegaal, Tim S. Maughan, Christopher G. Smith, Jeremy P. Cheadle, David Fisher, Richard Kaplan, Philip Quirke, Matthew T. Seymour, Susan D. Richman, Gerrit A. Meijer, Bauke Ylstra, Danielle A.M. Heideman, Anton F.J. de Haan, Cornelis J.A. Punt, and Miriam Koopman

- 5331** Smoking and Risk of Low- and High-Grade Prostate Cancer: Results from the REDUCE Study
Tammy Ho, Lauren E. Howard, Adriana C. Vidal, Leah Gerber, Daniel Moreira, Madeleine McKeever, Gerald Andriole, Ramiro Castro-Santamaria, and Stephen J. Freedland

CORRECTION

- 5339** Correction: Targeting miR21 Inhibits *In Vitro* and *In Vivo* Multiple Myeloma Cell Growth

AC icon indicates Author Choice

CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>

For more information please visit www.aacrjournals.org

Table of Contents

ABOUT THE COVER

The cover shows the expression of long noncoding RNAs in normal and malignant bladder urothelium as detected by microarray. Unsupervised hierarchical clustering reveals discrimination of normal, low-grade and high-grade malignant tissues. For details, see the article by Peter and colleagues on page 5311 of this issue.

